The research compound in Rybelsus^®

Rybelsus^® is a type 2 diabetes medicine from Novo Nordisk. Its active compound is Oral Semaglutide — which is what this catalogue supplies, as a research material.

This is not Rybelsus^®, and NOVALYTE LABS has no affiliation with Novo Nordisk. We supply the compound Oral Semaglutide for laboratory research only — not for human consumption, diagnostic, therapeutic or veterinary use. Rybelsus^® is a trademark of Novo Nordisk, referenced here only to identify the compound.

Rybelsus is the oral tablet formulation of semaglutide — the same active compound as Ozempic and Wegovy, delivered by a different route.

Making a peptide survive the stomach required co-formulation with SNAC, an absorption enhancer. Even so, oral bioavailability is around 1%, which is why tablet doses are expressed in milligrams where injectable doses are in fractions of one.

The oral formulation is listed here as a research material, not as the branded medicine.

Oral Semaglutide in this catalogue